• Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s Disease
• Acquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease (REGEN4HD), a Phase 1b/2a Clinical Trial Currently Enrolling Patients
• NeuroAirmid Shareholders Received $4.7 Million in Cash and Equity at Closing and are Eligible to Receive up to $5 Million on the First Anniversary of Closing and up to $48 Million in Success-based Milestones
• UCI Received a $12 Million Clinical Grant from the California Institute for Regenerative Medicine (CIRM) to support the REGEN4HD study

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.